Novel immunotherapy mechanism suppresses breast cancer development
CD4+ T helper 2 cells force breast cancer cells to revert to benign breast gland cells.
Contact Information
Boston, MAPhone: 617-726-2914
Shawn Demehri, MD, PhD is a board-certified dermatologist and a Principal Investigator at the Center for Cancer Immunology and Cutaneous Biology Research Center of Massachusetts General Hospital. Dr. Demehri attended Washington State University, where he obtained his bachelor’s degree in biology with honors. He received his medical (MD) and PhD degree in cell and molecular biology from Washington University in St. Louis. After completing his internship, Dr. Demehri completed a combined dermatology residency and postdoctoral fellowship in immunology at Washington University, twice receiving research fellowship awards from the Dermatology Foundation and American Skin Association.
Dr. Demehri is a recipient of American Academy of Dermatology Young Investigator Award and Burroughs Wellcome Fund Career Award for Medical Scientists and NIH Director's Early Independence Award. He has numerous peer-reviewed publications in reputable journals and has presented his work at the Society for Investigative Dermatology, Tumor Immunology and Gordon Research Conferences. Dr. Demehri is a physician-scientist performing basic science and translational research in the area of cancer immunology related to melanoma and non-melanoma skin cancers.
His research is focused on determining the role of the immune system in preventing the early stages of cancer development. Dr. Demehri’s clinical interests include cutaneous oncology with a focus on the detection and treatment of high-risk skin cancers, inflammatory skin diseases that predispose patients to skin cancer, skin cancer prevention and general dermatology.
For more information, please visit the Demehri Laboratory website.
Departments, Centers, & Programs:
Clinical Interests:
Treats:
Languages:
Mass General Dermatology
50 Staniford St.
Boston, MA 02114
Phone: 617-726-2914
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 hospital in New England based on U.S. News & World Report Best Hospitals for 2022-2023.
CD4+ T helper 2 cells force breast cancer cells to revert to benign breast gland cells.
Scientists discover that certain proteins surrounding organs and tissues switch off natural killer cells’ “killer” function. Blocking these interactions could re-activate the cells.
Mass General Cancer Center physician-scientists Shawn Demehri, MD, PhD, Areej El-Jawahri, MD, and Sara Pai, MD, PhD have been elected to the American Society for Clinical Investigation (ASCI) as part of ASCI's new class of members for 2022.
Populations at high risk of melanoma could particularly benefit from an approach that harnesses the immune powers of CD4+ T cells.
Researchers from Massachusetts General Hospital (MGH) have discovered a biological mechanism that transforms cells exposed to carcinogens from environmental factors like smoking and ultraviolet light into immunogenic cells that can be harnessed therapeutically to fight treatment-resistant cancers.
“Low-risk” human papillomaviruses appear to play an unwitting role in protecting people against skin cancer according to a new study published in Nature.